Corporate News
Director/PDMR Shareholding
26 April 2019
Following Admission of the new ordinary shares of 2.5p each ("Ordinary Shares") issued in the Placing announced on 8 April 2019, the directors shareholdings are as follows.
Name | Number of Shares acquired in the Placing | No of Ordinary Shares held | % of Ordinary Share Capital held |
Matthew Walls (and connected parties) | 1,000,000 | 1,525,000 | 0.58% |
Adam Reynolds (and connected parties) | 416,667 | 1,834,722 | 0.69% |
Barbara Spurrier (and connected parties) | 333,333 | 579,390 | 0.22% |
Total voting rights
Following Admission, the Company's enlarged issued share capital will comprise 264,946,675 Ordinary Shares. The Company does not hold any shares in treasury. Therefore, the total number of Ordinary Shares with voting rights will be 264,946,675. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries
Company: www.conceptaplc.com, Product: www.mylotus.com
Matthew Walls, Chairman
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nominated Adviser)
Neil Baldwin
Tel: +44 (0)20 368 3550
Novum Securities
Colin Rowbury
+44 (0) 20 7399 9400
About Concepta plc:
Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalised mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.
myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception
rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019.
myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.